Эриус

Quick links to important sections

Эриус

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Эриус

Property Description
Active Ingredient Desloratadine
Form Film-coated tablet, Oral solution
Pharmacological Class Second-generation Antihistamine
Common Use Symptomatic relief of allergic conditions
Origin Synthetic, Active metabolite of Loratadine

Core Identity and Purpose

Эриус is a medicinal preparation whose core function is to manage and relieve symptoms associated with systemic hypersensitivity reactions, such as those that cause allergic rhinitis. Its active component is Desloratadine, a potent and selective substance classified as a second-generation antihistamine.

Desloratadine functions as a long-acting histamine H1-receptor antagonist, meaning it selectively blocks the peripheral H1 receptors activated by histamine released during an allergic event. This action establishes the drug's role in providing symptomatic relief. As a key differentiating factor, Desloratadine is specifically the active metabolite of Loratadine, allowing it to exert its anti-allergic effect without requiring extensive conversion by the body.

Composition and Forms

The entire pharmacological activity of this product is attributable to Desloratadine, making it a single active ingredient product. This compound is manufactured for oral administration, ensuring a rapid systemic anti-allergic effect throughout the body.

The product is commonly supplied in two primary dosage form types: the solid film-coated tablet and the liquid oral solution. The oral solution is a key feature, as its liquid base facilitates administration to pediatric patient groups and others who may have difficulty swallowing solid forms. The design, as a selective peripheral blocker, results in a non-sedating profile for most individuals, which is a hallmark benefit clinically recognized for improving patient compliance.

What side effects are possible with Эриус?

Possible Side Effects and Safety Information

The safety profile for desloratadine (Эриус) is based on data from clinical trials and post-marketing surveillance, classified by regulatory authorities (such as EMA and FDA).

Adverse Reactions by Frequency

Side effects are categorized based on how often they have been reported in controlled studies or post-marketing data:

Frequency Examples of Adverse Reactions (Adults/Adolescents)
Common (≥ 1/100 to < 1/10) Headache, Fatigue, Dry mouth
Very Rare (< 1/10,000) Seizures, Hallucinations, Tachycardia, Hepatitis, Anaphylaxis
Not Known (Cannot be estimated) QT prolongation, Aggression, Weight increased, Insomnia

Serious and Clinically Significant Reactions

Rare but serious adverse reactions documented in regulatory sources include hypersensitivity reactions (such as anaphylaxis and angioedema), seizures, and effects on the heart (e.g., QT prolongation, arrhythmia). Disturbances of the liver (including hepatitis and jaundice) have also been reported.

Population-Specific Safety Considerations

  • Pediatrics: Reports of increased incidence of new-onset seizures have been noted in retrospective studies. Post-marketing events with unknown frequency include aggression and abnormal behaviour.
  • Severe Impairment: Desloratadine should be administered with caution in patients with a history of seizures and in those with severe renal or hepatic impairment.
  • Pregnancy and Lactation: As a precautionary measure, use during pregnancy is advised to be avoided. A decision must be made to discontinue breastfeeding or discontinue therapy during lactation.

Safety Restrictions

Desloratadine is contraindicated in patients with hypersensitivity to the active substance, any excipients, or to loratadine (the parent compound).

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for Эриус (Desloratadine) is based on data from regulatory surveillance and clinical trials involving elevated exposure.

Overdose Scope Official Regulatory Statement
Documented Manifestations The adverse event profile is similar to therapeutic doses, but the magnitude of effects can be higher, including symptoms like drowsiness, tachycardia, and palpitations.
Severe Outcomes Serious manifestations reported include seizures and QT prolongation.
Pediatric Notes For the paediatric population, the profile is similar, but the magnitude of effects may be higher, with post-marketing reports documenting arrhythmia and abnormal behaviour.
Elimination Constraints The drug is not eliminated by hemodialysis; its elimination by peritoneal dialysis is not known.

When Immediate Medical Help is Required

  • Immediately call emergency services (911/equivalent) if the individual has collapsed, had a seizure, has trouble breathing, or can’t be awakened.
  • In all other cases of suspected overdose, the Poison Control Helpline should be contacted, and medical attention sought.

Management Protocol Treatment consists of symptomatic and supportive treatment. Standard measures to remove unabsorbed active substance must be considered, as no specific antidote is known.


Connection to the Overall Overdose Profile Regulatory documents define overdose by the severity of its clinical presentation, requiring immediate emergency intervention when life-threatening symptoms are present. The official management strategy for overdose focuses entirely on supportive care and the removal of the substance, based on the documented finding that no specific pharmacological antidote is available.

Therapeutic Uses of Эриус

What Эриус treats: Main Uses and Benefits

The medication is commonly used to provide supportive relief for core conditions driven by allergic hypersensitivity, contributing to easing the overall symptom load on a daily basis. The medication is considered relevant in contexts involving heightened systemic burden where additional symptomatic support is needed for allergy-related symptoms.

Эриус is applied in addressing symptom clusters related to heightened physiological activity, may assist with maintaining functional stability, and supports general well-being when symptoms are more noticeable. It is commonly used for managing allergic rhinitis, which includes both seasonal and perennial forms, and for chronic idiopathic urticaria (CIU), known as chronic hives.

This supportive relief helps address symptom clusters that may become intense or disruptive, such as sneezing, runny nose, congestion, and itchy, watery eyes, and assists with easing the intensity of widespread pruritus (itching) and the presence of wheals on the skin.

“The sustained action contributes to improved comfort during periods of heightened symptoms.”

Quick Fact: Relief for Persistent Itching

The medication is relevant in conditions characterized by pronounced skin symptoms, specifically focusing on easing the intensity of pruritus and is used for managing the manifestations of chronic hives.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Эриус?

The population eligibility for Эриус (Desloratadine) is strictly defined by regulatory documents, separating authorized use from prohibited or conditional use. Use is established for Adults and Adolescents (12 years and older).

Category Eligibility Rule
Minimum Approved Age Oral solution is approved for children as young as 6 months for specific conditions; tablets are restricted to age 12 and older [Source 1.3, 1.4].
Absolute Contraindications Prohibited for individuals with known hypersensitivity to Desloratadine or Loratadine, or to the specific excipients, such as lactose in the tablets [Source 1.4, 3.6].
Organ Impairment Patients with severe hepatic or renal impairment require caution, and a modification of the administration schedule is officially recommended for adults in these cases [Source 2.2, 2.5].
Pregnancy and Lactation Use is not recommended during pregnancy (precautionary measure) and lactation (due to excretion into breast milk) [Source 1.2, 3.1].

Use is not established for infants under 6 months of age. Furthermore, patients with a medical or familial history of seizures should use the medicine with caution, as advised in the official product labeling [Source 1.6, 3.6].

What should I know about interactions with other medicines?

The official interaction profile for Desloratadine is defined by a set of pharmacokinetic findings that document how certain co-administered substances alter its concentration in the body.

Documented Pharmacokinetic Interactions

Co-administration with specific medicinal products is officially documented to significantly increase the plasma concentration (Cmax and AUC) of Desloratadine. This exposure increase is recognized as a pharmacokinetic interaction resulting from the inhibition of key clearance pathways.

Interacting Substance Official Effect on Desloratadine Exposure
Ketoconazole Increased plasma concentrations
Erythromycin Increased plasma concentrations
Cimetidine Increased plasma concentrations
Fluoxetine Increased plasma concentrations

These exposure changes are attributed to the interacting medicine's action as an inhibitor of both CYP enzymes and the P-glycoprotein (P-gp) efflux transporter.

Interactions with Food and Substances

Regulatory documentation confirms that Desloratadine does not potentiate the performance-impairing effects of alcohol. Furthermore, taking the drug with or without food does not affect its overall disposition in the body. No mandatory administration separation rules with other medicinal products are specified in the official regulatory texts.

Population-Specific Interaction Notes

Official data notes that patients with hepatic impairment or severe renal impairment exhibit a significantly higher increase in Desloratadine exposure (up to 2.5-fold) compared to healthy subjects. This is an important consideration within the official interaction profile.

Mechanism of Action

Mechanism of Action of Эриус (Desloratadine)

The pharmacological action of Эриус is based on two primary, mechanistically distinct domains that operate to modulate the acute hypersensitivity response. The molecule's action profile is a direct consequence of its highly targeted H1 antagonism and peripheral specificity.


The Core Mechanism of Histamine H1 Inverse Agonism

This domain covers the primary biological target: the peripheral Histamine H1 receptor. Эриус engages this receptor as an inverse agonist, stabilizing its inactive conformation to block the effects of released histamine. This molecular action prevents the receptor from initiating its signaling cascade, resulting in a functional blockade of H1-mediated signaling. This action modulates the rapid-onset physiological processes that are characteristic of H1 receptor activation, which include increased capillary permeability and sensory nerve signaling in peripheral tissues.


Secondary Modulation of Inflammatory Mediator Release

This domain addresses the molecule's non- H1 receptor effects. Эриус also exerts secondary effects by directly inhibiting the release of several other pro-inflammatory mediators, including certain cytokines and chemokines (e.g., IL-4, IL-8), from key immune cells (mast cells and basophils). This secondary mechanism restricts the activity of the inflammatory pathway, which is a component of the molecule's overall mechanistic action. This inhibition assists in limiting the further propagation of the inflammatory state, resulting in a reduction of inflammation and fluid extravasation at the tissue level.


Peripheral Selectivity and Action Kinetics

This domain explains the molecule's action pattern, driven by its limited ability to cross the blood-brain barrier ( BBB) and its slow dissociation kinetics from the H1 receptor. This targeted molecular design ensures that the mechanistic effect is concentrated in peripheral systems, engaging the mechanism with minimal central neural pathway involvement. This selective action pattern restricts overactive signaling within peripheral immune and vascular systems, resulting in a targeted physiological modulation of these tissues.

Dosage and Administration Information

How to Use Эриус: Official Administration Guidelines

Эриус (Desloratadine) is administered strictly via the oral route, with two primary approved forms: a 5 mg film-coated tablet and a 0.5 mg/ml oral solution. This standard administration route ensures systemic delivery of the active ingredient.

Dosage and Frequency Patterns

The standard regimen for adults and adolescents aged 12 years and older is a single dose of 5 mg once daily. Pediatric patients aged 6 to 11 years utilize a 2.5 mg dose, also taken once daily. All labeled doses are designed to be taken as a single daily quantity, ensuring a consistent schedule.

Administration may occur with or without food, providing flexibility for the user. For patients with severe renal or hepatic impairment, a reduced frequency is indicated, involving the administration of the 5 mg dose every other day. The duration of use is determined by the condition being addressed: for intermittent symptoms, treatment may be stopped once relief is achieved and resumed upon recurrence, whereas persistent symptoms generally require continuous use.

If a dose is missed, the dose is taken as soon as it is remembered, followed by a return to the regular schedule. Doses should not be doubled to compensate for the missed administration.

Recent Clinical Evidence

Research evidence / Overview of studies for Эриус (Desloratadine)


Evidence for Use in Allergic Rhinitis (AR)

The research into desloratadine has primarily used randomized, double-blind, placebo-controlled trials (RCTs). These studies are conducted during periods of increased symptom activity and applied in research contexts involving fluctuating or unstable symptoms of AR. The research monitored outcomes related to specific symptom scores for nasal and ocular manifestations (e.g., sneezing, runny nose, itchy eyes, and congestion). Outcomes also included functional measures and monitored patient-reported outcomes describing perceived discomfort and outcomes related to daily functioning and activity level. The evidence contributes to the broader understanding of symptom patterns observed across short-term and intermediate follow-up periods, typically ranging from two to six weeks.

Evidence for Use in Chronic Hives (Chronic Idiopathic Urticaria)

Research for Chronic Idiopathic Urticaria (CIU), or chronic hives, includes multiple randomized, controlled trials. These studies examined conditions characterized by fluctuating or episodic manifestations. The research focused on evaluating outcomes linked to physical discomfort, primarily examining the severity of pruritus (itching) and changes in the number and size of wheals (hives). Findings described patterns in the Urticaria Activity Score reported across the study groups, including the active substance group and the placebo group. The trials included adults and adolescents with conditions marked by functional limitations.


What is Still Uncertain About Эриус Research

The majority of published RCTs for desloratadine focused on exploring short-term changes in symptoms. Studies report on changes measured during these initial study periods, but the long-term effects are not fully established. Consequently, there is limited information for long-term outcomes related to the sustained status of allergic symptoms or the long-term patterns observed in chronic hives. Comparative evidence against a wide range of other similar allergy medicines is limited in head-to-head trials. Data for certain subgroups, such as older adults, also remain insufficient in the core regulatory studies.

Key Studies & References

  1. The Efficacy and Safety of High Dose (10 mg) of Desloratadine in the Treatment of Chronic Spontaneous Urticaria
  2. DESLORATADINE tablet - DailyMed - NIH (Full Prescribing Information/Label)
  3. Desloratadine: MedlinePlus Drug Information (NIH)

Frequently Asked Questions (FAQ)

Common questions about Эриус (FAQ)


Q: Does Эриус cause drowsiness or sleepiness?

A: According to official product information, drowsiness or sleepiness is noted as a possible side effect, but it is considered rare. This means that in clinical trials and regulatory reporting, it occurs in less than 1 in 10,000 patients. Information regarding potential effects on concentration is provided in the official product documents.


Q: What is the main active ingredient in Эриус?

A: The primary component responsible for the therapeutic effect of this medication is desloratadine. Desloratadine is classified as a non-sedating antihistamine that works by blocking histamine. Official regulatory documents identify this as the core pharmaceutical ingredient.


Q: Can I drink alcohol while taking Эриус?

A: Official studies and product information suggest that this medicine does not increase the effects of alcohol. However, individuals react differently to combinations of medicines and alcohol. Regulatory information indicates that individual susceptibility should be taken into account regarding alcohol consumption while using the medicine.


Q: How quickly does Эриус start to work?

A: Research studies indicate that the medication works quickly, with symptom relief typically beginning within 30 minutes of administration. This indicates that relief from allergy symptoms, such as a reduction in itching or sneezing, typically starts shortly after the medicine is taken. Official research supports this rapid onset of action.


Q: Is Эриус used to treat hives (urticaria)?

A: Yes, the regulatory indications confirm that this medicine is used to treat the symptoms of chronic idiopathic urticaria, commonly known as hives. Specifically, it is indicated for the relief of associated symptoms like itching and can reduce the size and total number of hives. This confirms its official use for managing the discomfort associated with this condition.

How should Эриус be stored and disposed of?

How to Store and Dispose of Эриус?

This section outlines the regulatory requirements for the storage and disposal of Desloratadine (Эриус).

Storage Condition Requirement
Temperature Do not store above 30 C (for specific tablet forms), or store in conditions that do not require special temperature precautions (varies by formulation).
Protection Keep the medicinal product in the original package to protect from moisture. If packaged in a bottle, keep it tightly closed to protect from light.
Accessibility Keep out of the sight and reach of children.
Disposal No special precautions are typically required for the disposal of unused medicinal product or waste material. Unused medication should generally be disposed of via drug take-back programs or placed in household trash after being mixed with undesirable substances and sealed.

Always store this medication strictly according to the labeled instructions to maintain its quality. Do not remove the medication from its original packaging until needed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Эриус found in:

A-Z Index: